Lexeo Therapeutics

📍 New York, United States🗓 Founded 2018👥 89 employees💰 Last funded May 2025
Biotechnology Research🌐 lexeotx.com
Website LinkedIn
Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimers disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.
3
Total investors
1
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
France
1
Investor activity2020–2025 · investors recorded per year
202012021120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Lexeo Therapeutics?
Lexeo Therapeutics has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did Lexeo Therapeutics last raise funding?
The most recent investment in Lexeo Therapeutics recorded on gritt.io was in May 2025.
When was Lexeo Therapeutics founded?
Lexeo Therapeutics was founded in 2018.
What industry is Lexeo Therapeutics in?
Lexeo Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Lexeo Therapeutics based?
Lexeo Therapeutics is headquartered in New York, United States.